NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Comfortage - AD Prevention Strategies
Comfortage - AD Prevention Strategies

NCT06896201

Active Not RecruitingNA

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions: Alzheimer Disease, Subjective Cognitive Impairment, Mild Cognitive Impairment

Interventions: Neuropsychological Assessments and Other Questionnaires, Blood Exams, Fluid Biomarkers, Genetics, Connectivity Analysis, Physical Activity, Healthentia

Countries: Italy

Study is Interventional, cross-sectional, clinical trial without drug and without device

Eligibility overview

Sex: ALL

Age: 50 Years to 85 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* subjective cognitive decline, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; normal performance on standardised cognitive tests adjusted for age, sex, and education; decline cannot be explained by psychiatric or other neurologic disease, medical disorder, medication, or substance use; no functional impact on daily life activities
* mild cognitive decline, defined as persistent decline in cognitive performance (in comparison with a previous status) reported by the subject or by an informed caregiver; or observed by change on longitudinal cognitive testing; cognitive performance below expected range for that individual based on cognitive test performance (adjusted for age, sex, and education); performs daily life activities independently (but cognitive difficulty may result in detectable but minimal functional impact on the more complex activities of daily life, either self-reported or corroborated by a study partner); Clinical Dementia Rating Scale = 0.5
* Ability to sign and understand the informed consent form

Exclusion Criteria:

* Age under 50 or over 85 years
* Non-native Italian speakers
* Non degenerative and secondary forms of dementia
* Previous or current participation in clinical trials with anti-amyloid agents
Locations (1)
  • Roma, Italy